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Hot Topic Lecture
Extra-adrenal regeneration of glucocorticoids by 11b-hydroxysteroid
dehydrogenase type 1: physiological regulator and pharmacological
target for energy partitioning
Brian R. Walker
University of Edinburgh, Endocrinology Unit, Centre for Cardiovascular Science, Queen’s Medical
Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
The major glucocorticoid in man, cortisol, plays important roles in regulating fuel metabolism,
energy partitioning and body fat distribution. In addition to the control of cortisol levels in
blood by the hypothalamic–pituitary–adrenal axis, intracellular cortisol levels within target
tissues can be controlled by local enzymes. 11b-Hydroxysteroid dehydrogenase type 1 (11b-
HSD1) catalyses the regeneration of active cortisol from inert cortisone, thereby amplifying
cortisol levels and glucocorticoid receptor activation in adipose tissue, liver and other tissues.
11b-HSD1 is under complex tissue-specific regulation and there is evidence that it adjusts local
cortisol concentrations independently of the plasma cortisol concentrations, e.g. in response to
changes in diet. In obesity 11b-HSD1 mRNA and activity in adipose tissue are increased. The
mechanism of this up-regulation remains uncertain; polymorphisms in the HSD11B1 gene have
been associated with metabolic complications of obesity, including hypertension and type
2 diabetes, but not with obesity per se. Extensive data have been obtained in mice with
transgenic over-expression of 11b-HSD1 in liver and adipocytes, targeted deletion of 11b-
HSD1, and using novel selective 11b-HSD1 inhibitors; these data support the use of 11b-HSD1
inhibitors to lower intracellular glucocorticoid levels and treat both obesity and its metabolic
complications. Moreover, in human subjects the non-selective ‘prototype’ inhibitor carbenox-
olone enhances insulin sensitivity. Results of clinical studies with novel potent selective 11b-
HSD1 inhibitors are therefore eagerly awaited. The present article focuses on the physiological
role of glucocorticoids in regulating energy partitioning, and the evidence that this process is
modulated by 11b-HSD1 in human subjects.
Glucocorticoids: 11b-Hydroxysteroid dehydrogenase: Energy partitioning:
Obesity: Diabetes mellitus
The intracellular enzyme 11b-hydroxysteroid dehydro-
genase type 1 (11b-HSD1) catalyses the interconversion
of the active 11-hydroxy glucocorticoid cortisol with
its inactive 11-keto metabolite cortisone. 11b-HSD1 is
predominantly a reductase in most circumstances, regen-
erating cortisol from cortisone and thereby increasing
intracellular cortisol concentrations. Since 11b-HSD1 is
co-localised with glucocorticoid receptors in many cells,
including in adipose tissue and liver, it is ideally positioned
to amplify local glucocorticoid action (Fig. 1). It follows
that chronically increasing 11b-HSD1 activity might
increase glucocorticoid receptor activation and thereby
promote obesity and its associated metabolic compli-
cations, while decreasing 11b-HSD1 may be a strategy to
reduce glucocorticoid action selectively in some tissues
and thereby reverse the metabolic complications of obe-
sity. In support of this hypothesis transgenic mice over-
expressing 11b-HSD1 in adipose tissue develop obesity
with all the features of the metabolic syndrome (Masuzaki
et al. 2001, 2003), while 11b-HSD1-knock-out mice are
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protected from obesity and its metabolic complications
(Kotelevtsev et al. 1997; Morton et al. 2001, 2004a).
Against this background there has been intense interest in
developing inhibitors of 11b-HSD1 to reduce glucocorti-
coid action selectively within metabolically-active tissues
such as adipose and liver, without blocking essential actions
of glucocorticoids during stress. Indeed, to date approxi-
mately eighteen pharmaceutical companies and other
organisations have filed patents for 11b-HSD1 inhibitors.
The influence of 11b-HSD1 in mice and its potential as
a therapeutic target in human subjects has been extensively
reviewed elsewhere (Seckl & Walker, 2001, 2004; Seckl
et al. 2004; Tomlinson et al. 2004b). The present article
will focus on what is known of the physiological role
of glucocorticoids in the regulation of fuel partitioning in
liver and adipose tissue, how this process is modulated by
11b-HSD1, and how it may be perturbed in obesity. It
draws, wherever possible, on results of experiments in
human subjects.
Glucocorticoids and control of energy partitioning
Responses to starvation and stress
Many investigators have remarked that the evolution of the
control of energy balance has been driven by intermittent
but prolonged periods of starvation and malnutrition, rather
than by relatively short periods of ample nutrition such as
most individuals enjoy today. Just one of the pathways that
respond to undernutrition is the hypothalamic–pituitary–
adrenal (HPA) axis, controlling the secretion of cortisol
from the adrenal cortex (Fig. 1). On starvation, cortisol
levels rise (Johnstone et al. 2004). A similar rise in
cortisol is induced by physical stressors, including trauma
and sepsis. In addition, cortisol exhibits marked diurnal
variation and levels are highest on waking. There are also
small rises in cortisol secretion after each meal (Rosmond
et al. 1998). The mechanisms of activation of the HPA axis
in starvation are poorly understood; by analogy with the
role of cytokines in mediating the cortisol response to
sepsis and trauma, changes in adipokines may be impor-
tant. For example, leptin has been shown to inhibit the
HPA axis (Heiman et al. 1997; Nowak et al. 2002), so that
a fall in leptin during starvation may be key to HPA axis
activation (Ahima et al. 1996).
Following a rise in cortisol secretion into plasma, respon-
ses mediated via glucocorticoid receptors are relatively
slow because they involve diffusion onto cytoplasmic
receptors, translocation of these activated receptors to
the nucleus, followed by alterations in gene transcription
and translation. Responses to increases in cortisol may
also be buffered through binding to corticosteroid-binding
globulin within the intravascular compartment, although
this binding is usually saturated in the upper physiological
range of cortisol concentrations so that the response to
increasing cortisol secretion is non-linear (Bamberger et al.
1996).
It is estimated that glucocorticoid receptors can interact
as transcription factors with as many as 30% of genes, so
it is not surprising that glucocorticoids induce a wide
range of responses. An important effect on bioenergetics is
to increase the turnover between free and stored energy
substrates (for review, see Andrews & Walker, 1999).
Thus, glucocorticoids increase cycling between glucose-6-
phosphate and glycogen and between NEFA and TAG. The
balance between free and stored substrates is determined
by other signals, notably insulin, with the increased turn-
over resulting in an amplified response. Glucocorticoids
also induce protein catabolism and gluconeogenesis, while
decreasing liver mitochondrial b-oxidation (Morton et al.
2001), thus encouraging hepatic release of fatty acids
and glucose as energy for peripheral tissues. In addition,
glucocorticoids alter signalling of other hormones that
regulate energy balance, including catecholamines and
insulin. Within the pancreas, glucocorticoids inhibit insulin
secretion (Delaunay et al. 1997). In the brain they stimu-
late food intake, particularly of fat (Castonguay, 1991) and
sugar (Epel et al. 2001). All these acute effects increase
the capacity for generation of energy to support skeletal
muscle metabolism over a few hours or days and thus
enhance the ability to ‘fight or flight’.
In addition to their effects on energy metabolism, gluco-
corticoids orchestrate many other aspects of the stress
response that optimise survival following trauma or infec-
tion (Sapolsky et al. 2000). They induce euphoria, prevent
sleep, suppress hippocampal memory retention, potentiate
vasoconstrictor responses, enhance renal Na retention,
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Fig. 1. Interactions between the hypothalamic–pituitary–adrenal
axis and 11b-hydroxysteroid dehydrogenases (11HSD) in the
control of glucocorticoid receptor activation. CRH, corticotrophin-
releasing hormone; ACTH, adrenocorticotrophin; CBG,
corticosteroid-binding globulin; 11HSD1, 11HSD type 1; ER, endo-
plasmic reticulum; GR, glucocorticoid receptor. In the kidney cortisol
is converted to cortisone by 11HSD type 2.
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suppress reproductive function and promote resolution of
inflammatory responses by the innate immune system.
They promote differentiation of immune and related cells,
including pre-adipocytes.
Chronic glucocorticoid excess
Although helpful in adapting to short-term stress, excessive
glucocorticoid action in the long term becomes maladap-
tive, particularly if this excessive action occurs in the
absence of starvation. This situation is exemplified in
Cushing’s syndrome, in which elevated circulating levels
of glucocorticoids, as a result of either iatrogenic anti-
inflammatory treatment or pathological secretion of
cortisol from the adrenal cortex, result in weight gain,
myopathy, hyperglycaemia, dyslipidaemia, hypertension,
mood disturbance, infertility and many other features
(Newell-Price et al. 2006).
Given that glucocorticoids promote the delivery of fuel
to skeletal muscle, the increase in TAG stores in adipose
tissue in Cushing’s syndrome appears paradoxical. This
paradox probably reflects the combination of elevated
glucocorticoid action with elevated insulin levels in indi-
viduals who are able to eat unrestricted energy and are not
consuming fuel by exercising heavily (Dallman et al.
2004). In these circumstances fatty acid esterification pre-
dominates over lipolysis and, combined with stimulation
of pre-adipocyte differentiation, results in expansion of
adipose tissue size.
Cushing’s syndrome is characterised by central (vis-
ceral) obesity, with relative sparing of subcutaneous adipose
tissue. This outcome probably reflects higher expression
of glucocorticoid receptors in visceral adipose tissue
(Bronnegard et al. 1990).
Responses to overnutrition and obesity
The parallels between the clinical features of Cushing’s
syndrome and the features of the metabolic syndrome
(visceral obesity, hyperglycaemia, hypertension) led to the
hypothesis that obesity is associated with glucocorticoid
excess (Bjorntorp, 1991). In several monogenic rodent
models obesity is accompanied by elevated circulating
glucocorticoid levels, and the obesity is prevented by
adrenalectomy. Hyperactivity of the HPA axis was thought
to reflect chronic stress. However, although there is some
evidence for greater stress responsiveness of the HPA axis
in obesity (Rosmond et al. 1998; Epel et al. 2000), stress
does not appear to explain HPA axis activation in meta-
bolic syndrome (Brunner et al. 2002). Most importantly, in
human obesity it appears that cortisol secretion (Marin
et al. 1992; Pasquali et al. 1993) is increased to match
elevated metabolic clearance (Strain et al. 1982; Andrew
et al. 1998; Lottenberg et al. 1998), and does not result in
increased plasma cortisol concentrations. Indeed, plasma
cortisol concentrations are generally lower amongst obese
subjects (Ljung et al. 1996; Walker et al. 2000; Reynolds
et al. 2003), i.e. inverse to the effects on the HPA axis seen
during starvation (see earlier; p. 2).
Glucocorticoid deficiency or blockade
Unfortunately, glucocorticoid deficiency (associated with
Addison’s disease or adrenocorticotrophin deficiency)
does not lend itself to detailed investigation, since it
is a life-threatening condition that requires immediate
corticosteroid-replacement therapy. However, the clinical
features are broadly the opposite of those in Cushing’s
syndrome, and include weight loss and hypoglycaemia.
The effects of the glucocorticoid receptor antago-
nist RU38486 (mifepristone) are broadly as predicted
by the effects of glucocorticoids described earlier.
Thus, RU38486 reduces blood glucose and ameliorates
insulin resistance in ob/ob mice (Gettys et al. 1997),
streptozotocin-induced diabetic mice (Bitar, 2001) and
high-fat-fed rats (Kusunoki et al. 1995), although it is
less effective in Zucker obese rats (Havel et al. 1996). In
healthy human subjects, however, acute dosing with
RU38486, although lowering serum TAG (Ottosson et al.
1995) and basal hepatic glucose output (Garrel et al. 1995),
has been reported to raise postprandial glucose and insulin
concentrations without affecting energy balance (Jobin
et al. 1996). Furthermore, in obese patients RU38486 does
not reverse hyperinsulinaemia or alter appetite (Kramlik
et al. 1993). These paradoxical results may be explained
because RU38486 blocks glucocorticoid receptors involved
in negative feedback control and this action produces
compensatory activation of the HPA axis. Moreover,
RU38486 is also a progesterone receptor antagonist, and
this action may influence energy homeostasis (Picard et al.
2002).
To avoid systemic effects RU38486 has been targetted
to the liver by conjugation to a bile acid. This strategy has
shown that liver glucocorticoid receptor blockade is suffi-
cient to improve hepatic glucose output and blood glucose
concentrations in Zucker obese rats (Jacobson et al. 2005),
a conclusion that is supported by experiments in which
glucocorticoid receptor translation has been prevented by
transgenesis (Opherk et al. 2004) or by using in vivo anti-
sense RNA constructs (Watts et al. 2005). Non-steroidal
glucocorticoid receptor modulators that are apparently
liver-specific have also been described, with promising
effects in animal models of diabetes mellitus (Link et al.
2005). Unfortunately, none of these compounds has yet
been evaluated in human subjects.
In summary, chronic glucocorticoid excess induces
obesity and associated metabolic syndrome. Although
glucocorticoid deficiency has not been studied as exten-
sively as glucocorticoid excess, there are sufficient data to
suggest that reducing glucocorticoid action may be a
valuable strategy to lower blood glucose and fatty acid
levels and enhance insulin sensitivity. Effects on long-term
control of body weight have, however, been inadequately
tested.
11b-Hydroxysteroid dehydrogenase type 1 in the
control of energy partitioning
The evidence that metabolism of glucocorticoids within
target tissues can influence access of ligands to receptors
over and above the control exerted by the HPA axis is
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remarkably strong in mice. The data suggest that adipose
tissue, as much as liver, is the key target tissue in which
glucocorticoid action influences susceptibility to obesity
and associated metabolic complications. Interestingly, 11b-
HSD1 activity in skeletal muscle is relatively trivial and
has not been shown to be important. Transgenic over-
expression of 11b-HSD1 within adipose tissue results in
elevated intra-adipose glucocorticoid levels, with asso-
ciated obesity, hyperglycaemia, dyslipidaemia and hyper-
tension (Masuzaki et al. 2001, 2003). However, a similar
level of over-expression in liver does not induce obesity or
hyperglycaemia, although there are changes in lipidaemia,
insulin sensitivity and blood pressure (Paterson et al.
2004). 11b-HSD1-knock-out mice on a high-fat diet
are protected from obesity and metabolic complications
(Kotelevtsev et al. 1997; Morton et al. 2001, 2004a).
Pharmacological inhibition of 11b-HSD1 has also been
achieved in mice. These inhibitors are effective in enhanc-
ing hepatic insulin sensitivity and lowering blood glucose
in diabetic mice and induce weight loss in obese mice,
at least in the short term (Alberts et al. 2002, 2003;
Hermanowski-Vosatka et al. 2005).
Although not the focus of the present review, it is worth
noting that some of the actions of 11b-HSD1 inhibitors in
mice may operate in tissues other than liver and adipose.
For example, 11b-HSD1 inhibition reduces the progression
of atheroma in apoE-knock-out mice (Hermanowski-
Vosatka et al. 2005), perhaps reflecting actions on the
enzyme within the vessel wall (Hadoke et al. 2006) or
within immune cells (Gilmour et al. 2006). Furthermore,
there may be effects of 11b-HSD1 on central control of
appetite (Densmore et al. 2006) and on insulin secretion
from pancreatic b-cells (Davani et al. 2000). These actions
remain largely unexplored in human subjects.
The ability of the human liver to convert pharmacolo-
gical doses of cortisone into cortisol has been recognised
since the earliest days of anti-inflammatory glucocorticoid
therapy. What is the evidence that 11b-HSD1 plays the
same key role in determining glucocorticoid action in liver
and/or adipose tissue in human subjects as it does in mice?
Contribution of 11b-hydroxysteroid dehydrogenase
type 1 to the glucocorticoid pool
The proportion of the plasma cortisol pool derived from
regeneration of cortisol by 11b-HSD1 has recently been
quantified and found to be substantial. These measure-
ments were achieved in human subjects (Andrew et al.
2002) using a novel stable-isotope tracer, in which meta-
bolism of [9,11,12,12-2H4]cortisol is compared with meta-
bolism of [9,12,12-2H3]cortisol; 11b-reductase activity
generates [2H3]cortisol but not [
2H4]cortisol, so that the
ratio between the two can be used to calculate cortisol
regeneration rates. Basu et al. (2004) have estimated
that peripheral regeneration of cortisol in healthy men is
approximately 11 nmol/min at a time when adrenal cortisol
secretion is approximately 38 nmol/min. All this peripheral
regeneration of cortisol could be accounted for by its
appearance in the hepatic vein, suggesting that it occurs
almost entirely in the splanchnic circulation.
It remains uncertain how much of this splanchnic
regeneration of cortisol occurs outside of the liver. Andrew
et al. (2005) have measured the regeneration of cortisol in
the liver following oral cortisone administration and have
deduced that approximately one-third of splanchnic 11b-
HSD1 activity is hepatic while two-thirds may be accoun-
ted for by visceral components, probably visceral adipose
tissue. Importantly, these conclusions have yet to be vali-
dated by direct measurements either in the portal vein or in
venous drainage across other potential major sites of 11b-
HSD1 activity such as subcutaneous adipose tissue. Indeed,
cortisol concentrations in the portal vein (Aldhahi et al.
2004) or superficial epigastric veins (Katz et al. 1999) have
not been shown to be greater than those in the arterial
circulation, although cortisone levels in veins draining
adipose tissue are lower. It is known, however, that infu-
sion of cortisone directly into subcutaneous adipose tissue
results in local production of cortisol (Sandeep et al. 2005).
Regulation of 11b-hydroxysteroid dehydrogenase type 1
A wide variety of factors are known to regulate 11b-HSD1
mRNA levels and activity in rodents and in isolated cells
in culture (for review, see Tomlinson et al. 2004b). A
number of these factors are important modulators of energy
balance, including insulin, liver X receptor agonists,
growth hormone, insulin-like growth factor 1, cytokines
and PPAR agonists. Intriguingly, high-fat feeding of mice
(Morton et al. 2004b) or rats (Drake et al. 2005) results
in down-regulation of 11b-HSD1 selectively within the
adipose tissue. Although a tissue-specific promoter for
11b-HSD1 has been identified in lung and placenta (Bruley
et al. 2006), the basis for tissue-specific regulation in liver
and adipose tissue is not known.
Recent research has begun to address the regulation of
11b-HSD1 in healthy human subjects, and suggests that
the enzyme is influenced by nutritional status. Thus, a
single mixed meal induces a rise in whole-body rates of
regeneration of cortisol by 11b-HSD1, although the organ
responsible for this process is not clear (Basu et al. 2006).
Recent data (Wake et al. 2006) suggest that it is mediated
by hyperinsulinaemia. In the longer term, energy restric-
tion in obese subjects has been associated with an increase
in 11b-HSD1 in subcutaneous adipose tissue (Tomlinson
et al. 2004a), although this finding is not universal (Engeli
et al. 2004), perhaps because of differences in the diet
being followed at the time biopsies were obtained. More
investigation is required, but it appears that 11b-HSD1
may respond to signals of energy balance in an analogous
way to the HPA axis, and modulate tissue levels of cortisol
over and above changes in plasma cortisol concentrations.
Consequences of loss of 11b-hydroxysteroid
dehydrogenase type 1 in human subjects
Results from clinical trials with novel selective 11b-HSD1
inhibitors are eagerly awaited. In the meantime, pharma-
cological inhibition of 11b-HSD1 with the anti-ulcer drug
carbenoxolone has provided evidence that cortisol regen-
eration influences insulin sensitivity, particularly glycogen
turnover, in healthy human subjects and in patients with
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type 2 diabetes (Walker et al. 1995; Andrews et al. 2003).
However, carbenoxolone is neither selective nor very
potent and does not appear to inhibit 11b-HSD1 in adipose
tissue, perhaps explaining its lack of efficacy in obesity
(Sandeep et al. 2005).
Congenital deficiency of 11b-HSD1 (‘apparent cortisone
reductase deficiency’) has been described (Phillipou et al.
1996), but the phenotype is dominated by the con-
sequences of enhanced metabolic clearance rate of cortisol
(a result of the lack of regeneration in peripheral tissues),
with compensatory activation of the HPA axis resulting
in adrenal androgen excess, hirsutism and oligomenorrhoea
in women. These women do not appear to be protected
from obesity and any influence on susceptibility to meta-
bolic complications is questionable. The molecular basis
for the disorder is also complex. It appears most likely
that inactivating mutations in hexose-6-phosphate dehy-
drogenase (Draper et al. 2003), an enzyme closely asso-
ciated with 11b-HSD1 in the lumen of the endoplasmic
reticulum, result in an inadequate supply of NADPH
cofactor for 11b-HSD1 reductase activity. In hexose-6-
phosphate dehydrogenase-deficient mice this situation
results in a ‘switch’ of 11b-HSD1 to the dehydrogenase
direction (Lavery et al. 2006). As yet, it is unclear whether
variations in hexose-6-phosphate dehydrogenase activity
provide a means for post-transcriptional physiological
regulation of 11b-HSD1 activity (Hewitt et al. 2005).
Elevated 11b-hydroxysteroid dehydrogenase
type 1 in obesity
Given the similarities between Cushing’s syndrome and
idiopathic obesity, coupled with the lack of elevation of
plasma cortisol levels in the latter, it was hypothesised
that increases in 11b-HSD1 within adipose tissue may be
a causative factor in obesity (Bujalska et al. 1997).
Initial studies relied on measurements of cortisol :cortisone
metabolites in urine (Andrew et al. 1998; Fraser et al.
1999), an assay that is probably unreliable in obesity, when
several cortisol and cortisone-metabolising enzymes are
dysregulated (Andrew et al. 1998). Of greater importance,
the conversion of an oral dose of cortisone into cortisol on
first-pass metabolism in the liver was found to be lower,
not higher, in obesity (Stewart et al. 1999). However,
parallel studies in obese rodents revealed tissue-specific
dysregulation of 11b-HSD1, with a reduction in enzyme
activity and mRNA levels in liver accompanied by an
increase in the enzyme in adipose tissue (Livingstone et al.
2000). A number of groups (Rask et al. 2001, 2002;
Paulmyer-Lacroix et al. 2002; Lindsay et al. 2003; Wake
et al. 2003; Engeli et al. 2004; Kannisto et al. 2004) have
now confirmed this observation in biopsies of sub-
cutaneous adipose tissue from obese people. Nonetheless,
there may not be a relationship between 11b-HSD1 in
visceral adipose tissue and body composition (Tomlinson
et al. 2002; Goedecke et al. 2006). Importantly, in both
the whole body (Sandeep et al. 2005) and the splanchnic
circulation (Basu et al. 2005) there is no difference in
cortisol regeneration rates measured with a [2H4]-cortisol
tracer between obese and lean subjects, presumably
because an up-regulation in adipose tissue is balanced by
a down-regulation in liver. However, direct in vivo measure-
ments using microdialysis in subcutaneous adipose tissue
suggest a substantial increase in the rate of conversion of
cortisone to cortisol (Sandeep et al. 2005). The subtle
counter-regulatory mechanisms that operate between dif-
ferent tissues, and different sites of adipose tissue, may be
key to how glucocorticoids modulate predisposition to
obesity and associated morbidities.
To understand the basis for the increase in adipose
11b-HSD1 in obesity, several non-coding polymorphisms
in the HSD11B1 gene encoding the enzyme have been
identified (Draper et al. 2002; Nair et al. 2004). None of
these polymorphisms is associated with obesity, but they
have been linked to the increased risk of diabetes and
hypertension in two populations (Franks et al. 2004; Nair
et al. 2004). Moreover, a polymorphism that predicts lower
11b-HSD1 expression (Draper et al. 2003) and is protec-
tive against diabetes is also under-represented in patients
who are both obese and have polycystic ovary syndrome
(Gambineri et al. 2006), in which lower 11b-HSD1 may
enhance cortisol clearance and increase adrenal androgen
production. This finding suggests that 11b-HSD1 may not
underpin the accumulation of TAG in adipose tissue, but
rather may determine the severity of the metabolic con-
sequences when obesity occurs.
Conclusions
The identification of 11b-HSD1 as a local amplifier of
glucocorticoid receptor activation has provided novel
insights into many facets of the stress response. This new
paradigm allows that responses can be regulated not only
by the HPA axis but also by the sensitivity of each cell and
tissue to a given level of cortisol in the circulation. Thus
far, investigations in human subjects have only scratched at
the surface in understanding the influence of 11b-HSD1 in
many different components of the stress response, and
have focused on its role in energy partitioning and
in obesity. Here, increased regeneration of cortisol within
adipose tissue has caught the imagination of many inves-
tigators, and the potential for enzyme inhibition in the
treatment of obesity and type 2 diabetes is an exciting, but
as yet unproven, strategy. Arguably, the more important
observations are the initial suggestions that 11b-HSD1 is
exquisitely regulated, including by feeding, so that the
enzyme may be a key component in the homeostatic
adaptation to variations in macronutrient intake.
Acknowledgements
Our research is supported in large part by the British Heart
Foundation and Wellcome Trust.
References
Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B,
Maratos-Flier E & Flier JS (1996) Role of leptin in the
neuroendocrine response to fasting. Nature 382, 250–252.
Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G,
Larsson C, Ronquist-Nii Y, Ohman B & Abrahmsen L (2002)
Hot Topic Lecture 5
Selective inhibition of 11beta-hydroxysteroid dehydrogenase
type 1 decreases blood glucose concentrations in hypergly-
caemic mice. Diabetologia 45, 1528–1532.
Alberts P, Nilsson C, Selen G, Engblom NHM, Norlin S,
Klingstrom G et al. (2003) Selective inhibition of 11b-
hydroxysteroid dehydrogenase type 1 improves hepatic insulin
sensitivity in hyperglycaemic mice strains. Endocrinology 144,
4755–4762.
Aldhahi W, Mun E & Goldfine AB (2004) Portal and peripheral
cortisol levels in obese humans. Diabetologia 47, 833–836.
Andrew R, Phillips DIW & Walker BR (1998) Obesity and
gender influence cortisol secretion and metabolism in man.
Journal of Clinical Endocrinology and Metabolism 83, 1806–
1809.
Andrew R, Smith K, Jones GC & Walker BR (2002) Distin-
guishing the activities of 11b-hydroxysteroid dehydrogenases
in vivo using isotopically labelled cortisol. Journal of Clinical
Endocrinology and Metabolism 87, 277–285.
Andrew R, Westerbacka J, Wahren J, Yki-Jarvinen H & Walker
BR (2005) The contribution of visceral adipose tissue to
splanchnic cortisol production in healthy humans. Diabetes 54,
1364–1370.
Andrews RC, Rooyackers O & Walker BR (2003) Effects of the
11beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone
on insulin sensitivity in men with type 2 diabetes. Journal of
Clinical Endocrinology and Metabolism 88, 285–291.
Andrews RC & Walker BR (1999) Glucocorticoids and insulin
resistance: old hormones, new targets. Clinical Science 96,
513–523.
Bamberger CM, Schulte HM & Chrousos GP (1996) Molecular
determinants of glucocorticoid receptor function and tissue
sensitivity to glucocorticoids. Endocrine Reviews 17, 245–261.
Basu R, Singh R, Basu A, Johnson CM & Rizza RA (2006)
Effect of nutrient ingestion on total-body and splanchnic cor-
tisol production in humans. Diabetes 55, 667–674.
Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson CM,
Toffolo G, Cobelli C & Rizza RA (2004) Splanchnic cortisol
production occurs in humans – evidence for conversion
of cortisone to cortisol via the 11-b hydroxysteroid dehy-
drogenase type 1 pathway. Diabetes 53, 2051–2059.
Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson MC,
Toffolo G, Cobelli C & Rizza RA (2005) Obesity and type 2
diabetes do not alter splanchnic cortisol production in humans.
Journal of Clinical Endocrinology and Metabolism 90, 3919–
3926.
Bitar MS (2001) Co-administration of etomoxir and RU-486
mitigates insulin resistance in hepatic and muscular tissues of
STZ-induced diabetic rats. Hormone and Metabolic Research
33, 577–584.
Bjorntorp P (1991) Visceral fat accumulation: the missing link
between psychosocial factors and cardiovascular disease?
Journal of Internal Medicine 230, 195–201.
Bronnegard M, Arner P & Hellstrom L (1990) Glucocorticoid
receptor messenger ribonucleic acid in different regions of
human adipose tissue. Endocrinology 127, 1689–1696.
Bruley C, Lyons V, Worsley AG, Wilde MD, Darlington GD,
Morton NM, Seckl JR & Chapman KE (2006) A novel
promoter for the 11beta-hydroxysteroid dehydrogenase type 1
gene is active in lung and is C/EBPalpha independent. Endo-
crinology 147, 2879–2885.
Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P,
Juneja M et al. (2002) Adrenocortical, autonomic and inflam-
matory causes of the metabolic syndrome: nested case-control
study. Circulation 106, 2659–2665.
Bujalska IJ, Kumar S & Stewart PM (1997) Does central obesity
reflect ‘Cushing’s disease of the omentum’? Lancet 349, 1210–
1213.
Castonguay TW (1991) Glucocorticoids as modulators in the
control of feeding. Brain Research Bulletin 27, 423–428.
Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H &
Akana SF (2004) Minireview: glucocorticoids – food intake,
abdominal obesity, and wealthy nations in 2004. Endocrinol-
ogy 145, 2633–2638.
Davani B, Khan A, Hult M, Martensson E, Okret S, Efendic S,
Jornvall H & Oppermann UCT (2000) Type 1 11beta-hydro-
xysteroid dehydrogenase mediates glucocorticoid activation
and insulin release in pancreatic islets. Journal of Biological
Chemistry 275, 34 841–34 844.
Delaunay F, Khan A, Cintra A, Davani B, Ling Z-C, Andersson
A, Ostenson C-G, Gustafsson J-A, Efendic S & Okret S (1997)
Pancreatic beta cells are important targets for the diabetogenic
effects of glucocorticoids. Journal of Clinical Investigation
100, 2094–2098.
Densmore VS, Morton NM, Mullins JJ & Seckl JR (2006) 11b-
Hydroxysteroid dehydrogenase type 1 induction in the arcuate
nucleus by high fat feeding: a novel constraint to hyperphagia?
Endocrinology 147, 4487–4495.
Drake AJ, Livingstone DEW, Andrew R, Seckl JR, Morton NM
& Walker BR (2005) Reduced adipose glucocorticoid reacti-
vation and increased hepatic glucocorticoid clearance as an
early adaptation to high fat feeding in rats. Endocrinology 146,
913–919.
Draper N, Echwald SM, Lavery GG, Walker EA, Fraser
R, Davies E et al. (2002) Association studies between
microsatellite markers within the gene encoding human
11beta-hydroxysteroid dehydrogenase type 1 and body mass
index, waist to hip ratio, and glucocorticoid metabolism.
Journal of Clinical Endocrinology and Metabolism 87, 4984–
4990.
Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM,
Arlt W et al. (2003) Mutations in the genes encoding 11b-
hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate
dehydrogenase interact to cause cortisone reductase deficiency.
Nature Genetics 34, 434–439.
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U,
Janke J, Luft FC & Sharma AM (2004) Regulation of 11b-
hydroxysteroid dehydrogenase genes in human adipose tissue:
influence of central obesity and weight loss. Obesity Research
12, 9–17.
Epel E, Lapidus R, McEwen B & Brownell K (2001) Stress may
add bite to appetite in women: a laboratory study of stress-
induced cortisol and eating behavior. Psychoneuroendocrinol-
ogy 26, 37–49.
Epel ES, McEwen B, Seeman T, Matthews K, Castellazzo G,
Brownell KD, Bell J & Ickovics JR (2000) Stress and body
shape: stress-induced cortisol secretion is consistently greater
among women with central fat. Psychosomatic Medicine 62,
623–632.
Franks PW, Knowler WC, Nair S, Koska J, Lee Y-H, Lindsay
RS, Walker BR, Looker HC, Permana PA, Tataranni PA &
Hanson RL (2004) Interaction between an 11betaHSD1 gene
variant and birth era modifies the risk of hypertension in Pima
Indians. Hypertension 44, 681–688.
Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E &
Connell JMC (1999) Cortisol effects on body mass, blood
pressure, and cholesterol in the general population. Hyper-
tension 33, 1364–1368.
Gambineri A, Vicennati V, Tomassoni F, Pagotto U, Pasquali R
& Walker BR (2006) Genetic variation in 11b-hydroxysteroid
dehydrogenase type 1 predicts hyperandrogenism amongst lean
women with Polycystic Ovary Syndrome. Journal of Clinical
Endocrinology and Metabolism 91, 2295–2302.
Garrel DR, Moussali R, De Oliveira A, Lesiege D & Lariviere F
(1995) RU 486 prevents the acute effects of cortisol on glucose
6 B. R. Walker
and leucine metabolism. Journal of Clinical Endocrinology
and Metabolism 80, 379–385.
Gettys TW, Watson PM, Taylor IL & Collins S (1997) RU-486
(Mifepristone) ameliorates diabetes but does not correct defi-
cient beta-adrenergic signalling in adipocytes from mature
C57BL/6J-ob/ob mice. International Journal of Obesity and
Related Metabolic Disorders 21, 865–873.
Gilmour JS, Coutinho AE, Cailhier JF, Man TY, Clay M, Thomas
G, Harris HJ, Mullins JJ, Seckl JR, Savill JS & Chapman KE
(2006) Local amplification of glucocorticoids by 11beta-
hydroxysteroid dehydrogenase type 1 promotes macrophage
phagocytosis of apoptotic leukocytes. Journal of Immunology
176, 7605–7611.
Goedecke JH, Wake DJ, Levitt NS, Lambert EV, Collins MR,
Morton NM, Seckl JR & Walker BR (2006) Glucocorti-
coid metabolism within superficial rather than visceral
adipose tissues is associated with features of the metabolic
syndrome in South African women. Clinical Endocrinology 65,
81–87.
Hadoke PWF, Macdonald L, Logie JJ, Small GR, Dover AR &
Walker BR (2006) Intravascular glucocorticoid metabolism as
a modulator of vascular structure and function. Cellular and
Molecular Life Sciences 63, 565–578.
Havel PJ, Busch BL, Curry DL, Johnson PR, Dallman MF &
Stern JS (1996) Predominately glucocorticoid agonist actions
of RU-486 in young specific-pathogen-free Zucker rats.
American Journal of Physiology 271, R710–R717.
Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW &
Flier JS (1997) Leptin inhibition of the hypothalamic-pituitary-
adrenal axis in response to stress. Endocrinology 138, 3859–
3863.
Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY,
Hernandez M, Koo GC et al. (2005) 11b-HSD1 inhibition
ameliorates metabolic syndrome and prevents progression of
atherosclerosis in mice. Journal of Experimental Medicine 202,
517–527.
Hewitt KN, Walker EA & Stewart PM (2005) Hexose-6-
phosphate dehydrogenase and redox control of 11b-hydro-
xysteroid dehydrogenase type 1 activity. Endocrinology 146,
2539–2543.
Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J,
Zinker B et al. (2005) Hepatic glucocorticoid receptor antag-
onism is sufficient to reduce elevated hepatic glucose output
and improve glucose control in animal models of type 2
diabetes. Journal of Pharmacology and Experimental Ther-
apeutics 314, 191–200.
Jobin N, de Jonge L & Garrel DR (1996) Effects of RU 486 on
energy expenditure and meal tolerance in normal men. Journal
of the American College of Nutrition 15, 283–288.
Johnstone AM, Faber P, Andrew R, Gibney ER, Elia M, Lobley
G, Stubbs RJ & Walker BR (2004) Influence of short-term
dietary weight loss on cortisol secretion and metabolism in
obese men. European Journal of Endocrinology 150, 185–194.
Kannisto K, Pietilainen KH, Ehrenborg E, Rissanen A, Kaprio J,
Hamsten A & Yki-Jarvinen H (2004) Overexpression of
11beta-hydroxy steroid dehydrogenase-1 in adipose tissue is
associated with acquired obesity and features of insulin resis-
tance: Studies in young adult monozygotic twins. Journal of
Clinical Endocrinology and Metabolism 89, 4414–4421.
Katz JR, Mohamed-Ali V, Wood PJ, Yudkin JS & Coppack SW
(1999) An in vivo study of the cortisol-cortisone shuttle in
subcutaneous abdominal adipose tissue. Clinical Endocrinol-
ogy 50, 63–68.
Kotelevtsev YV, Holmes MC, Burchell A, Houston PM, Scholl
D, Jamieson PM, Best R, Brown RW, Edwards CRW, Seckl JR
& Mullins JJ (1997) 11b-Hydroxysteroid dehydrogenase type 1
knockout mice show attenuated glucocorticoid inducible
responses and resist hyperglycaemia on obesity and stress.
Proceedings of the National Academy of Sciences USA 94,
14 924–14 929.
Kramlik SK, Altemus M & Castonguay TW (1993) The effects
of the acute administration of RU 486 on dietary fat preference
in fasted lean and obese men. Physiology and Behavior 54,
717–724.
Kusunoki M, Cooney GJ, Hara T & Storlien LH (1995) Ameli-
oration of high-fat feeding-induced insulin resistance in skele-
tal muscle with the antiglucocorticoid RU486. Diabetes 44,
718–720.
Lavery G, Walker EA, Draper N, Jeyasuria P, Marcos J,
Shackleton CHL, Parker KL, White PC & Stewart PM (2006)
Hexose-6-phosphate dehydrogenase knock-out mice lack
11b-hydroxysteroid dehydrogenase type 1-mediated gluco-
corticoid regeneration. Journal of Biological Chemistry 281,
6546–6551.
Lindsay RS, Tataranni A, Permana P, Livingstone DEW, Wake
DJ & Walker BR (2003) Subcutaneous adipose 11b-hydro-
xysteroid dehydrogenase type 1 activity and mRNA levels are
associated with adiposity and insulinaemia in Pima Indians and
Caucasians. Journal of Clinical Endocrinology and Metabolism
88, 2738–2744.
Link JT, Sorensen B, Patel J, Grynfarb M, Goos-Nilsson A, Wang
J et al. (2005) Antidiabetic activity of passive nonsteroidal
glucocorticoid receptor modulators. Journal of Medicinal
Chemistry 48, 5295–5304.
Livingstone DEW, Jones GC, Smith K, Andrew R, Kenyon CJ &
Walker BR (2000) Understanding the role of glucocorticoids in
obesity: tissue-specific alterations of corticosterone metabolism
in obese Zucker rats. Endocrinology 141, 560–563.
Ljung T, Andersson B, Bengtsson B, Bjorntorp P & Marin P
(1996) Inhibition of cortisol secretion by dexamethasone in
relation to body fat distribution: a dose-response study. Obesity
Research 4, 277–282.
Lottenberg SA, Giannella-Neto D, Derendorf H, Rocha M, Bosco
A, Carvalho SV, Moretti AE, Lerario AC & Wajchenberg BL
(1998) Effect of fat distribution on the pharmacokinetics of
cortisol in obesity. International Journal of Clinical Pharma-
cology and Therapeutics 36, 501–505.
Marin P, Darin M, Amemiya T, Andersson B, Jern S & Bjorntorp
P (1992) Cortisol secretion in relation to body fat distribution
in obese premenopausal women. Metabolism 41, 882–886.
Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ,
Seckl JR & Flier JS (2001) A transgenic model of visceral
obesity and the metabolic syndrome. Science 294, 2166–2170.
Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK,
Morton NM, Paterson JM et al. (2003) Transgenic amplifica-
tion of glucocorticoid action in adipose tissue causes high
blood pressure in mice. Journal of Clinical Investigation 112,
83–90.
Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins
JJ & Seckl JR (2001) Improved lipid and lipoprotein profile,
hepatic insulin sensitivity, and glucose tolerance in 11b-
hydroxysteroid dehydrogenase type 1 null mice. Journal of
Biological Chemistry 276, 41 293–41 300.
Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B,
Fievet C, Walker BR, Flier JS, Mullins JJ & Seckl JR (2004a)
Novel adipose tissue-mediated resistance to diet-induced
visceral obesity in 11b-hydroxysteroid dehydrogenase type 1
deficient mice. Diabetes 53, 931–938.
Morton NM, Ramage L & Seckl JR (2004b) Down-regulation of
adipose 11b-hydroxysteroid dehydrogenase type 1 by high-fat
feeding in mice: a potential adaptive mechanism counteracting
metabolic disease. Endocrinology 145, 2707–2712.
Nair S, Lee YH, Lindsay RS, Walker BR, Tataranni PA, Bogardus
C, Baier LJ & Permana PA (2004) 11beta-Hydroxysteroid
Hot Topic Lecture 7
dehydrogenase Type 1: Genetic polymorphisms are associated
with Type 2 diabetes in Pima Indians independently of obesity
and expression in adipocyte and muscle. Diabetologia 47,
1088–1095.
Newell-Price J, Bertagna X, Grossman AB & Nieman LK (2006)
Cushing’s syndrome. Lancet 367, 1605–1617.
Nowak KW, Pierzchala-Koziec K, Tortorella C, Nussdorfer GG
& Malendowicz LK (2002) Effects of prolonged leptin infusion
on rat pituitary-adrenocortical function. International Journal
of Molecular Medicine 9, 61–64.
Opherk C, Tronche F, Kellendonk C, Kohlmuller D, Schulze A,
Schmid W & Schutz G (2004) Inactivation of the glucocorti-
coid receptor in hepatocytes leads to fasting hypoglycemia and
ameliorates hyperglycemia in streptozotocin-induced diabetes
mellitus. Molecular Endocrinology 18, 1346–1353.
Ottosson M, Marin P, Karason K, Elander A & Bjorntorp P
(1995) Blockade of the glucocorticoid receptor with RU 486:
effects in vitro and in vivo on human adipose tissue lipoprotein
lipase activity. Obesity Research 3, 233–240.
Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi
L, Flamia R, Labate AMM & Barabara L (1993) The
hypothalamic-pituitary-adrenal axis in obese women with dif-
ferent patterns of body fat distribution. Journal of Clinical
Endocrinology and Metabolism 77, 341–346.
Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC,
Staels B, Seckl JR & Mullins JJ (2004) Metabolic syndrome
without obesity: hepatic overexpression of 11b-hydroxysteroid
dehydrogenase type 1 in transgenic mice. Proceedings of the
National Academy of Sciences USA 101, 7088–7093.
Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi M-C & Grino
M (2002) Expression of the mRNA coding for 11b-
hydroxysteroid dehydrogenase type 1 in adipose tissue
from obese patients: an in situ hybridization study. Journal of
Clinical Endocrinology and Metabolism 87, 2701–2705.
Phillipou G, Palermo M & Shackleton CHL (1996) Apparent
cortisone reductase deficiency; a unique form of hypercortiso-
lism. Journal of Clinical Endocrinology and Metabolism 81,
3855–3860.
Picard F, Wanatabe M, Schoonjans K, Lydon J, O’Malley BW &
Auwerx J (2002) Progesterone receptor knockout mice have an
improved glucose homeostasis secondary to beta-cell pro-
liferation. Proceedings of the National Academy of Sciences
USA 99, 15 644–15 648.
Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DEW,
Johnson O & Walker BR (2001) Tissue-specific dysregulation
of cortisol metabolism in human obesity. Journal of Clinical
Endocrinology and Metabolism 86, 1418–1421.
Rask E, Walker BR, Soderberg S, Livingstone DEW, Eliasson M,
Johnson O, Andrew R & Olsson T (2002) Tissue-specific
changes in peripheral cortisol metabolism in obese women;
increased adipose 11b-hydroxysteroid dehydrogenase type 1
activity. Journal of Clinical Endocrinology and Metabolism
87, 3330–3336.
Reynolds RM, Syddall HE, Walker BR, Wood PJ & Phillips DIW
(2003) Predicting cardiovascular risk factors from plasma cor-
tisol measured during oral glucose tolerance tests. Metabolism:
Clinical and Experimental 52, 524–527.
Rosmond R, Dallman MF & Bjorntorp P (1998) Stress-related
cortisol secretion in men: relationships with abdominal obesity
and endocrine, metabolic and haemodynamic abnormalities.
Journal of Clinical Endocrinology and Metabolism 83, 1853–
1859.
Sandeep TC, Andrew R, Homer NZM, Andrews RC, Smith K
& Walker BR (2005) Increased in vivo regeneration of cortisol
in adipose tissue in human obesity and effects of the
11b-hydroxysteroid dehydrogenase type 1 inhibitor carbenox-
olone. Diabetes 54, 872–879.
Sapolsky RM, Romero LM & Munck AU (2000) How do gluco-
corticoids influence stress responses? Integrating permissive,
suppressive, stimulatory, and preparative actions. Endocrine
Reviews 21, 55–89.
Seckl JR, Morton NM, Chapman KE & Walker BR (2004)
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase
in adipose tissue. Recent Progress in Hormone Research 59,
359–393.
Seckl JR & Walker BR (2001) 11b-Hydroxysteroid dehy-
drogenase type 1 – a tissue-specific amplifier of glucocorticoid
action. Endocrinology 142, 1371–1376.
Seckl JR & Walker BR (2004) 11beta-hydroxysteroid dehy-
drogenase type 1 as a modulator of glucocorticoid action: From
metabolism to memory. Trends in Endocrinology and Meta-
bolism 15, 418–424.
Stewart PM, Boulton A, Kumar S, Clark PMS & Shackleton
CHL (1999) Cortisol metabolism in human obesity: impaired
cortisone-cortisol conversion in subjects with central adiposity.
Journal of Clinical Endocrinology and Metabolism 84, 1022–
1027.
Strain GW, Zumoff B, Kream J, Strain JJ, Levin J & Fukushima
D (1982) Sex difference in the influence of obesity on the
24 hr mean plasma concentration of cortisol. Metabolism 31,
209–212.
Tomlinson JW, Moore JS, Clark PMS, Holder G, Shakespeare
L & Stewart PM (2004a) Weight loss increases 11beta-
hydroxysteroid dehydrogenase type 1 expression in human
adipose tissue. Journal of Clinical Endocrinology and Meta-
bolism 89, 2711–2716.
Tomlinson JW, Sinha B, Bujalska I, Hewison M & Stewart PM
(2002) Expression of 11beta-hydroxysteroid dehydrogenase
type 1 in adipose tissue is not increased in human obesity.
Journal of Clinical Endocrinology and Metabolism 87, 5630–
5635.
Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG,
Cooper MS, Hewison M & Stewart PM (2004b) 11beta-
Hydroxysteroid dehydrogenase type 1: A tissue-specific
regulator of glucocorticoid response. Endocrine Reviews 25,
831–866.
Wake DJ, Homer NZM, Andrew R & Walker BR (2006) Acute
in vivo regulation of 11b-hydroxysteroid dehydrogenase type 1
activity by insulin and intralipid infusions in humans. Journal
of Clinical Endocrinology and Metabolism 91, 4682–4688.
Wake DJ, Rask E, Livingstone DEW, Soderberg S, Olsson T &
Walker BR (2003) Local and systemic impact of transcrip-
tional upregulation of 11b-hydroxysteroid dehydrogenase type
1 in adipose tissue in human obesity. Journal of Clinical
Endocrinology and Metabolism 88, 2983–2988.
Walker BR, Connacher AA, Lindsay RM, Webb DJ & Edwards
CRW (1995) Carbenoxolone increases hepatic insulin sensi-
tivity in man: a novel role for 11-oxosteroid reductase in
enhancing glucocorticoid receptor activation. Journal of Clin-
ical Endocrinology and Metabolism 80, 3155–3159.
Walker BR, Soderberg S, Lindahl B & Olsson T (2000) Inde-
pendent effects of obesity and cortisol in predicting cardio-
vascular risk factors in men and women. Journal of Internal
Medicine 247, 198–204.
Watts LM, Manchem VP, Leedom TA, Rivard AL, McKay RA,
Bao D et al. (2005) Reduction of hepatic and adipose tissue
glucocorticoid receptor expression with antisense oligonucleo-
tides improves hyperglycemia and hyperlipidemia in diabetic
rodents without causing systemic glucocorticoid antagonism.
Diabetes 54, 1846–1853.
8 B. R. Walker
